Home Investing Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Investing

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

by admin
written by admin

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.

You may also like

Netflix’s advertising strategy shift is starting to pay...

Procter & Gamble earnings top estimates, but shrinking...

P&G’s weak quarter is a clearing event that...

Procter & Gamble is selling diapers made with...

United Airlines could hit record earnings after strong...

Johnson & Johnson forecasts 2026 profit above Wall...

Netflix posts narrow earnings beat, reports 325 million...

3M forecasts annual profit below estimates amid sluggish...

Earnings playbook: Netflix and this chipmaker are among...

BlackRock’s earnings pass our test with flying colors....

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.

9 − 1 =

Privacy Policy - Terms and Conditions